Method of obtaining protection against bystander allergen

Abstract

The present invention relates to a method of obtaining protection against, simultaneously, a specific allergen and a by-stander allergen. The method comprises the administration of a compound comprising an allergen binding domain and a Fc domain, wherein the bystander allergen is unrelated to the allergen bound by the allergen binding domain.

1 . A method for obtaining cross-protection against one or more bystander allergens, said method comprising: 
 administering a compound comprising an allergen binding domain and a Fc domain, wherein said bystander allergens are unrelated to the allergen bound by said allergen binding domain.    
     
     
         2 . The method according to  claim 1 , wherein said compound is an antibody.  
     
     
         3 . The method according to  claim 2 , wherein said antibody is an IgG isotype antibody.  
     
     
         4 . The method according to  claim 1 , wherein said administration is intranasal or by inhalation.  
     
     
         5 . A pharmaceutical composition for the treatment of an allergic disease, said pharmaceutical composition comprising: 
 at least one compound comprising an allergen binding domain or allergen binding domains and a Fc domain,    wherein said allergic disease is caused by at least one allergen other than the allergen or allergens bound by the allergen binding domain or allergen binding domains.    
     
     
         6 . The pharmaceutical composition of  claim 5 , wherein said compound is an antibody.  
     
     
         7 . The pharmaceutical composition of  claim 6 , wherein said antibody is an IgG isotype antibody.  
     
     
         8 . The pharmaceutical composition of  claim 5 , wherein said allergic disease is allergic asthma.  
     
     
         9 . The pharmaceutical composition of  claim 5 , wherein said allergic disease is allergic rhinitis.  
     
     
         10 . The pharmaceutical composition of  claim 6 , wherein said allergic disease is allergic asthma.  
     
     
         11 . The pharmaceutical composition of  claim 6 , wherein said allergic disease is allergic rhinitis.  
     
     
         12 . The pharmaceutical composition of  claim 7 , wherein said allergic disease is allergic asthma.  
     
     
         13 . The pharmaceutical composition  claim 7 , wherein said allergic disease is allergic rhinitis.  
     
     
         14 . The method according to  claim 2 , wherein said administration is intranasal or by inhalation.  
     
     
         15 . The method according to  claim 3 , wherein said administration is intranasal or by inhalation.